2-Carba cyclic phosphatidic acid inhibits lipopolysaccharide-induced prostaglandin E2 production in a human macrophage cell line

Yuki Shibaike, Mari Goto, Chinatsu Ogawa, Shingo Nakajima, Keisuke Yoshikawa, Tetsuyuki Kobayashi, Kimiko Murakami-Murofushi

A R T I C L E   I N F O

Keywords:
2ccPA
Prostaglandin E2
Anti-inflammatory
THP-1 monocytes

A B S T R A C T

Cyclic phosphatidic acid (cPA) is a naturally occurring phospholipid mediator that contains a unique cyclic phosphate ring at the sn-2 and sn-3 positions of its glycerol backbone. Using mouse models for multiple sclerosis (cuprizone-induced demyelination and experimental autoimmune encephalomyelitis) and traumatic brain injury, we revealed that cPA and its metabolically stabilized cPA derivative, 2-carba-cPA (2ccPA), have potential to protect against neuroinflammation. In this study, we investigated whether 2ccPA has anti-inflammatory effect on peripheral immune function or not using inflammation-induced macrophages-like cell line, THP-1 monocytes differentiated by phorbol 12-myristate 13-acetate (PMA). Lipopolysaccharide (LPS)-stimulated THP-1 cells were found to have higher expression of the mRNAs of several inflammation-related cytokines and of the enzyme cyclooxygenase-2 (Cox-2); however, when THP-1 cells were stimulated by LPS in the presence of 2ccPA, the increase in the expression of pro-inflammatory cytokine and Cox-2 mRNA was attenuated. 2ccPA treatment also decreased the amount of prostaglandin E2 (PGE2) produced by LPS-stimulated THP-1 cells and decreased expression of the mRNA of prostaglandin E receptor 2 (EP2, PTGER2), a PGE2 receptor that mediates inflammation. These results indicate that 2ccPA has anti-inflammatory properties.

1. Introduction

Macrophages play important roles in the host defense system via the phagocytosis and release of inflammation-associated enzyme (cyclooxygenase-2, Cox-2) and various cytokines, such as pro- (interleukin [IL]-1β), IL-6, tumor necrosis factor [TNF]-α) and anti-inflammatory cytokines (transforming growth factor [TGF]-β) [1,2]. Cox-2 is an enzyme that synthesizes prostaglandin (PG) E2, a lipid mediator, which is responsible for inflammation and pain [3]; this enzyme is therefore one of the targets of non-steroidal anti-inflammatory drugs. Moreover, the release of pro-inflammatory cytokines is also responsible for systemic inflammation. We therefore surmise that attenuating the expression of Cox-2 and pro-inflammatory cytokines in activated macrophages could relieve inflammation.

Cyclic phosphatidic acid (cPA) is a lysophospholipid structurally similar to lysophosphatidic acid (LPA), first isolated from the myxamoebae of a true slime mold, Physarum polycephalum, in 1992 [4]. cPA was later found in mammalian tissues and normal and diseased serum [5–10]. We previously reported that cPA attenuates neuropathic pain and neuroinflammation [11,12]. These results suggested that cPA could be a therapeutic compound for these diseases. To develop this idea, we synthesized several cPA derivative compounds. 2ccPA is one of the stabilized derivative compounds of cPA in which the phosphate oxygen has been replaced with a methylene group at the sn-2 position [13–15]. Our previous study has demonstrated that 2ccPA administration reduced demyelination in a mouse model of multiple sclerosis via suppression of microglial activation and the NLRP3 inflammasome [16]. Moreover, 2ccPA reduced the damage associated with traumatic brain injury (TBI) induced using stab wound surgery with vertical needle injury and suppressed the expression of pro-inflammatory cytokines (IL-
1β, IL-6, and TNF-α) [17]. Although these experiments have demonstrated the anti-inflammatory effects of 2ccPA on the central nervous system (CNS), it is still unclear whether 2ccPA exerts anti-inflammatory effects in the peripheral immune system.

In this study, to gain insight into the anti-inflammatory function of 2ccPA upon exposure to infectious stimuli, we investigated the effect of 2ccPA on cytokines and Cox-2 mRNA expression using a lipopolysaccharide (LPS)-stimulated human macrophage cell line. In our experiment, we found that 2ccPA attenuated the increase in the expression of Cox-2 mRNA. Therefore, we examined the effect of 2ccPA on arachidonic cascade and found that 2ccPA has regulatory effect on the production of members of the arachidonic cascade.

2. Materials and methods

2.1. Pharmacological agents

1-oleoyl-2-O-carba-cPA (2ccPA 18:1) was chemically synthesized as previously described [1]. Bovine serum albumin (BSA; fraction V, fatty acid free) and lipopolysaccharide (LPS; from Escherichia coli O111:B4) were purchased from Sigma-Aldrich (St. Louis, MO). 2ccPA was dissolved in phosphate-buffered saline (PBS) containing 0.1% (w/v) BSA at final concentrations of 1 mM.

2.2. Cell culture and treatment

THP-1 cells, purchased from JCRB Cell Bank (Osaka, Japan), were cultured with RPMI1640 containing 10% heat-inactivated fetal bovine serum (FBS, Biowest, FL) at 37 °C (95% humidity, 5% CO2). Differentiation into macrophages was induced by the addition of 100 nM of phorbol 12-myristate 13-acetate (PMA, Wako, Tokyo, Japan) to the cells, and then cells were incubated for 48 h. The culture medium was replaced with fresh serum-free RPMI1640 to achieve serum starvation. After 16 h, 1 μg/mL of LPS was added to the differentiated THP-1 cells. For experiments to assess the effect of 2ccPA on the cells, various concentrations of 2ccPA or vehicle (0.1% BSA/PBS) was added together with LPS.

2.3. Western blot analysis

THP-1 cells were collected using 0.125 M Tris-HCl (pH 6.8) containing 4% sodium dodecyl sulfate, 20% glycerol, 10% 2-mercaptoethanol and 0.01% bromophenol blue. Proteins were separated using a 10% acrylamide gel in a SDS-PAGE, and then the separated proteins were transferred to a polyvinylidene fluoride membrane (Millipore). After blocking with 5% skim milk for 1 h, the membrane was washed several times with Tris buffered saline containing 0.1% Tween 20 (TBST). Primary antibody for anti-CD11b antibodies (1:1000 dilution, Cell Signaling Technology, Inc., MA) or with anti-GAPDH antibodies (1:1000 dilution, Cell Signaling Technology, Inc.) diluted with Can Get Signal immunoreaction enhancer solutions (TOYOBO Co., Ltd., Osaka, Japan) were incubated overnight. Next, following three rounds of washing with TBST, it was treated with horseradish peroxidase-conjugated anti-rabbit IgG (1:2500 dilution; Cell Signaling Technology, Inc.) for 2 h. Immunodetection was performed using an enhanced chemiluminescence system (Bio-Rad Laboratories, Inc., CA) and ImageQuant LAS 4000 (GE healthcare UK Ltd., Buckinghamshire, UK).

2.4. Measurement of PGE2 produced by differentiated THP-1 cells

To measure the concentration of secreted PGE2, LPS (1 μg/mL) was applied along with 2ccPA or vehicle (0.1% BSA/PBS) after serum starvation at final concentrations of 1, 3, and 10 μM. After 6 h, the culture media were collected and PGE2 concentration was measured using ELISA (R&D Systems, Inc. MN) according to the manufacturer's protocol.

### Table 1

| Gene | Primer Sequence |
|------|-----------------|
| Cdc11b (ITGAM) | Forward 5′-AGAACAATATGCAGAAGAC-3′<br>Reverse 5′-TGATGCTGATGACAATG-3′<br>Reverse 5′-TGATGCTGATGACAATG-3′<br>Reverse 5′-TGATGCTGATGACAATG-3′<br>Reverse 5′-TGATGCTGATGACAATG-3′ |
| IL-1α (IL1A) [23] | Forward 5′-GCTCAAGTGAGGAAAGAAG-3′<br>Reverse 5′-CTGCTGCTGCTGTCTGCTG-3′<br>Reverse 5′-CTGCTGCTGCTGTCTGCTG-3′<br>Reverse 5′-CTGCTGCTGCTGTCTGCTG-3′<br>Reverse 5′-CTGCTGCTGCTGTCTGCTG-3′ |
| IL-1β (IL1B) [24] | Forward 5′-GCAGGATGACCTGATGAT-3′<br>Reverse 5′-AGACATACAAAGCCCTTGTGCT-3′<br>Reverse 5′-AGACATACAAAGCCCTTGTGCT-3′<br>Reverse 5′-AGACATACAAAGCCCTTGTGCT-3′<br>Reverse 5′-AGACATACAAAGCCCTTGTGCT-3′ |
| IL-6 (IL6) [24] | Forward 5′-GTTGAAACAGGCTGAGGCTG-3′<br>Reverse 5′-ACTGAAGAGTCGGCCAGGAAG-3′<br>Reverse 5′-ACTGAAGAGTCGGCCAGGAAG-3′<br>Reverse 5′-ACTGAAGAGTCGGCCAGGAAG-3′<br>Reverse 5′-ACTGAAGAGTCGGCCAGGAAG-3′ |
| IL-8 (CXCL8) [25] | Forward 5′-AGGAACCCCTCTCAGCTGTGTTAC-3′<br>Reverse 5′-ATCGAGGGTTCGTCGAGGCT-3′<br>Reverse 5′-ATCGAGGGTTCGTCGAGGCT-3′<br>Reverse 5′-ATCGAGGGTTCGTCGAGGCT-3′<br>Reverse 5′-ATCGAGGGTTCGTCGAGGCT-3′ |
| TNF-α (TNF) [24] | Forward 5′-TGAAGATGTCGTGCTTCTCCA-3′<br>Reverse 5′-GCCTGGTGTGAGCCATATT-3′<br>Reverse 5′-GCCTGGTGTGAGCCATATT-3′<br>Reverse 5′-GCCTGGTGTGAGCCATATT-3′<br>Reverse 5′-GCCTGGTGTGAGCCATATT-3′ |
| Cox-2 (PTGS2) [26] | Forward 5′-CAGCACTTACAGGATCTACATG-3′<br>Reverse 5′-CCGGGCTCACCAACAAAGT-3′<br>Reverse 5′-CCGGGCTCACCAACAAAGT-3′<br>Reverse 5′-CCGGGCTCACCAACAAAGT-3′<br>Reverse 5′-CCGGGCTCACCAACAAAGT-3′ |
| TGF-β (TGFBI) [24] | Forward 5′-CAGAGGCTCCATGTCGACC-3′<br>Reverse 5′-AGGGCAAGAGCCTGTC-3′<br>Reverse 5′-AGGGCAAGAGCCTGTC-3′<br>Reverse 5′-AGGGCAAGAGCCTGTC-3′<br>Reverse 5′-AGGGCAAGAGCCTGTC-3′ |
| IL1RA (IL1RN) [27] | Forward 5′-GGATCTATCCGGAGGAAAGAT-3′<br>Reverse 5′-CCTTGGTACGAGATATGTT-3′<br>Reverse 5′-CCTTGGTACGAGATATGTT-3′<br>Reverse 5′-CCTTGGTACGAGATATGTT-3′<br>Reverse 5′-CCTTGGTACGAGATATGTT-3′ |
| IL-10 (IL10) [24] | Forward 5′-ATGGTCGTCGCTTCACTGACTGTC-3′<br>Reverse 5′-CCCCAAGTAGCTATGAGGCGAT-3′<br>Reverse 5′-CCCCAAGTAGCTATGAGGCGAT-3′<br>Reverse 5′-CCCCAAGTAGCTATGAGGCGAT-3′<br>Reverse 5′-CCCCAAGTAGCTATGAGGCGAT-3′ |
| EP2 (PTGER2) [28] | Forward 5′-CTGCTGTCGCCCTTCACTGTT-3′<br>Reverse 5′-ATGGGGATGTTAGGGAATG-3′<br>Reverse 5′-ATGGGGATGTTAGGGAATG-3′<br>Reverse 5′-ATGGGGATGTTAGGGAATG-3′<br>Reverse 5′-ATGGGGATGTTAGGGAATG-3′ |
| EP4 (PTGER4) [28] | Forward 5′-CCGGGCTCACCAACAAAGT-3′<br>Reverse 5′-CCGGGCTCACCAACAAAGT-3′<br>Reverse 5′-CCGGGCTCACCAACAAAGT-3′<br>Reverse 5′-CCGGGCTCACCAACAAAGT-3′<br>Reverse 5′-CCGGGCTCACCAACAAAGT-3′ |

2.5. Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA was extracted from cultured cells using TRI reagent® (Molecular Research Center, Inc., OH) according to the manufacturer's instructions. cDNA was synthesized using a PrimeScript RT reagent kit (Takara Bio, Inc.). To quantify the mRNA levels of the genes of interest and LPA receptors, real-time RT-PCR was performed using the THUNDERBIRD SYBR qPCR Mix (Toyobo, Osaka, Japan) and the lightCycler 96 system (Roche, Tokyo, Japan). Gene-specific primer sets for LPA receptors have been described in a previous report [18]. Other primer sets are described in Table 1. The data were calculated based on the Cq values and the expression of each gene was normalized to that of GAPDH.

2.6. Statistical analyses

All values are reported as mean ± standard error. Statistical analysis was performed using Prism 6 (GraphPad). Significant difference was assessed by the Student's t-test for pair comparison and Bonferroni's correction for multiple comparisons. All experiments were independently repeated at least 4 times and representative data are shown.

3. Results and discussion

3.1. Altered expression levels of LPA receptors (LPARs) during THP-1 cell differentiation

PMA (100 nM) treatment for 48 h morphologically changed THP-1 cells to adhere to the plastic culture dishes. We collected the adherent cells and confirmed the mRNA and protein expression of CD11b, a pan-macrophage marker. Because CD11b expression was increased in PMA-treated THP-1 cells (Fig. 1A and B), we used these adherent cells as being representative of human macrophage for subsequent experiments.

To investigate the effect of 2ccPA on PMA-treated THP-1 cells, we first investigated the mRNA expression of LPA receptors, which are considered candidate targets of 2ccPA, in THP-1 and PMA-treated THP-1 cells.
be required to control the formation of actin stress fibers upon treatment with PMA, increased expression of LPA6 might suggest that when circulating monocytes become adherent macrophages (Fig. 1C and D). In THP-1 cells, LPA1, LPA2, and LPA6 mRNA expression were higher than those of other LPA receptors. In PMA-treated THP-1 cells, the mRNA expression of LPA6 increased apparently. It is known that LPA6 couples to G12/13, and induces actin stress fiber formation via G12/13/RhoA/ROCK activation [19]. These results suggest that when circulating monocytes become adherent macrophages upon treatment with PMA, increased expression of LPA6 might be required to control the formation of actin stress fibers.

3.2. Expression of genes for inflammation-related cytokines and enzyme

To induce an inflammatory response, the PMA-treated THP-1 cells were stimulated with LPS. In our study, the mRNA expression levels of anti-inflammatory cytokines (IL-1RA IL-10, TGF-β) did not increase following LPS exposure; however, those of all pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, IL-8, and TNF-α) increased (Fig. 2A). The fold changes in the mRNA expression of TNF-α and Cox-2, PGE2 synthesizing enzyme, were remarkable (Fig. 2B). Maximal expression of most pro-inflammatory cytokines was observed after around 4 h of stimulation, except TNF-α, the maximal expression of which was achieved after 2 h of stimulation.

3.3. Effect of 2ccPA on inflammatory functions of PMA-treated THP-1 cells

To investigate the effect of 2ccPA on LPS-induced pro-inflammatory cytokine expression in macrophages, PMA-treated THP-1 cells were simultaneously exposed to 2ccPA and LPS. The addition of 2ccPA attenuated the increased expression of IL-1β, IL-6, IL-8, TNF-α, and Cox-2 mRNA caused by the exposure to LPS, particularly for IL-6 and Cox-2 (Fig. 3). 2ccPA had no effect on the mRNA expression of anti-inflammatory cytokines with or without LPS stimulation (data not shown).

Cox-2 is an enzyme involved in the synthesis of prostaglandin (PG) E2, a lipid mediator, which is responsible for inflammation and pain [3]. Therefore, we focused on the effect of 2ccPA on the attenuation of Cox-2 mRNA expression. As expected, 10 μM of 2ccPA significantly decreased the release of PGE2 from macrophages (Fig. 4A).

We also investigated the expression of PGE2 receptors. PGE2 acts via four specific G protein-coupled receptors (EP1-4). Although the expression level of EP1 and EP3 receptor mRNA expression was very low or undetectable in PMA-treated THP-1 cells (data not shown), the expression of EP2 and EP4 mRNA increased following LPS stimulation (Fig. 4B and C). EP2 signaling is reported to be associated with both pro- and anti-inflammatory effects upon LPS stimulation [20], while EP4 receptors are known to play a role in the anti-inflammatory response [21]. Interestingly, the increase in EP2 mRNA expression caused by LPS was abolished by co-treatment with 2ccPA, whereas 2ccPA did not affect the LPS-stimulated increase in EP4 mRNA expression (Fig. 4B and C). These results indicate that 2ccPA may modulate inflammation by downregulating Cox-2 mRNA expression and thereby PGE2 production. Remarkably, we had previously demonstrated that 2ccPA decreases cuprizone-induced demyelination and motor dysfunction [16]. The increase in the expression levels of EP2 receptor has been suggested to parallel the increase in Cox-2 mRNA expression in a cuprizone-induced demyelination mouse model [22]. Although it is still unclear whether the regulation of the peripheral immune system by 2ccPA contributes to the suppression of neuronal inflammation, 2ccPA might decrease the expression level of Cox-2 and EP2 mRNA, and the resultant decrease in the expression of PGE2 could partially contribute to the attenuation of neuroinflammation.

In summary, LPS-induced inflammation in PMA-treated THP-1 cells was attenuated by co-treatment with 2ccPA. Further, 2ccPA decreased the expression of mRNA of inflammatory enzyme Cox-2, and thereby the production of PGE2. These results revealed that 2ccPA has regulatory effects on the arachidonic acid cascade, which suggests the potential therapeutic effects of 2ccPA on inflammatory disease through its anti-inflammatory functions.

COI

The authors declare no conflicts of interest associated with this manuscript.

Acknowledgments

This study was supported by Japan Agency for Medical Research and Development (AMED). The authors gratefully acknowledge the work of past and present members of Murofushi and Kobayashi laboratory in Ochanomizu University. M.G. thanks timely assistance from the Research Organization for the Promotion of Global Women's
Fig. 2. Variation in cytokine and Cox-2 mRNA expression after LPS stimulation in differentiated THP-1 cells. To measure mRNA expression, differentiated THP-1 cells were cultured with LPS (1 μg/mL) for the time indicated. (A) IL-1RA, TGF-β, IL-10, IL-1α, IL-1β, IL-6, IL-8, and (B) TNF-α and Cox-2 mRNA levels were determined using quantitative real-time PCR. Data represent the mean ± SEM of triplicate independent experiments. One-way ANOVA followed by Bonferroni's post-hoc comparisons tests were performed. (*p < 0.001, **p < 0.0001 vs. 0 time).

Fig. 3. Effect of 2ccPA on LPS-induced cytokines and Cox-2 mRNA expression and PGE2 secretion in differentiated THP-1 cells. Differentiated THP-1 cells were incubated with LPS (1 μg/mL) along with or without 2ccPA (1, 10 μM). Cells were collected after 4 h of incubation and mRNA expressions were analyzed by real-time PCR. The data were calculated based on the Cq values, and the expression of each gene was normalized to the levels of GAPDH. The data were calculated as the relative induction compared to that of controls (without LPS treatment). Data are presented as the mean ± SEM, n = 4. Statistical analysis was performed using a Bonferroni’s test. (*p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001 vs. Vehicle).
mRNA expressions were analyzed by real-time PCR. (*p < 0.05; **p < 0.01 vs. Vehicle without LPA, #P < 0.05 vs. Vehicle with LPA).

Leadership, Ochanomizu University, with respect to academic support for woman researchers with young children.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bbrep.2019.100668.

References

[1] A.G. Eliopoulos, C.D. Dumitru, C. Wang, J. Cho, P.N. Tsichlis, Induction of COX-2 by LPS in macrophages is regulated by Tp2-dependent CREB activation signals, EMBO J. 21 (2002) 4831–4840.
[2] G.A. Duque, A. Descotes-Exon, Macrophage cytokine involvement in immunity and infectious diseases, Front. Immunol. 5 (2014) 491.
[3] E. Ricciotti, G.A. FitzGerald, Prostaglandins and inflammation, Arterioscler. Thromb. Vasc. Biol. 31 (2011) 986–1000.
[4] K. Murakami-Murofushi, M. Shiota, K. Kaji, S. Yoshida, H. Murofushi, Inhibition of eukaryotic DNA polymerase alpha with a novel lysophosphatic acid (PHYLPA) isolated from myxoamoebae of Physarum polycephalum, J. Biol. Chem. 267 (1992) 21512–21517.
[5] T. Kobayashi, Y. Tanaka-Ishii, R. Taguchi, H. Ikezawa, K. Murakami-Murofushi, Existence of a bioactive lipid, cyclic phosphatic acid, bound to human serum albumin, Life Sci. 65 (1999) 2185–2191.
[6] L. Shan, S. Li, K. Jaffe, L. Davis, Quantitative determination of cyclic phosphatic acid in human sera by LC/ESI/MS/MS, J. Chromatogr. B 862 (2008) 161–169.
[7] M.P. Cala, J. Aldana, J. Medina, J. Sanchez, J. Guio, J. Wist, R.J.W. Meesters, Multiplatform plasma metabolic and lipid fingerprinting of breast cancer: a pilot control-case study in Colombian Hispanic women, PloS One 13 (2) (2018) e0190656.
[8] P.L. Wood, M. Steinman, E. Erol, C. Carter, U. Christmann, A. Verma, Lipidomic analysis of immune activation in equine leptospirosis and Leptospiros-vaccinated horses, PloS One 13 (2) (2018) e0193424.
[9] Y. Shimizu, M. Ishikawa, M. Gotoh, T. Fukasawa, S. Yamamoto, K. Iwasa, K. Yoshikawa, K. Murakami-Murofushi, Quantitative determination of cyclic phosphatic acid and its carbox analog in mouse organs and plasma using LC/MS/ MS, J. Chromatogr. B 1076 (2018) 15–21.
[10] K. Fukasawa, S. Nakajima, M. Gotoh, S. Tanaka, H. Murofushi, K. Murakami-Murofushi, Qualitative and quantitative comparison of cyclic phosphatic acid and its related lipid species in rat serum by LC/MS/MS using hydrophilic interaction liquid chromatography, J. Chromatogr. A 1567 (2018) 177–184.
[11] V. Kakuchi, J. Nagai, M. Gotoh, H. Hotta, H. Murofushi, T. Ogawa, H. Ueda, K. Murakami-Murofushi, The non-oxidative effects of cyclic phosphatic acid and its derivative in animal models of acute and chronic pain, Mol. Pain 7 (2011) 33.
[12] S. Yamamoto, M. Gotoh, Y. Kawamura, K. Yamashina, S. Yagishita, T. Awaji, K. Murayama, K. Murakami-Murofushi, K. Yoshikawa, Cyclic phosphatic acid treatment suppress cuprizone-induced demyelination and motor dysfunction in mice, Eur. J. Pharmacol. 741 (2014) 17–24.
[13] D.L. Baker, Y. Fujisawa, H.R. Pigg, R. Tsukahara, S. Kobayashi, H. Murofushi, A. Uchiyama, K. Murakami-Murofushi, E. Koh, R.W. Bandle, H.S. Byun, R. Bittman, D. Fan, M. Murph, G.B. Mills, G. Tigyi, Carbox analogs of cyclic phosphatic acid are selectivive inhibitors of autotaxin and cancer cell invasion and metastasis, J. Biol. Chem. 281 (2006) 22786–22793.
[14] A. Uchiyama, M. Mukai, Y. Fujiwara, S. Kobayashi, N. Kawai, H. Murofushi, M. Inoue, S. Enoki, Y. Tanaka, T. Niki, T. Kobayashi, G. Tigyi, K. Murakami-Murofushi, Inhibition of transcellular tumor cell migration and metastasis by novel carbox-derivatives of cyclic phosphatic acid, Biochim. Biophys. Acta 1771 (2007) 103–112.
[15] E. Nozaki, M. Gotoh, H. Hotta, S. Hanazawa, S. Kobayashi, K. Murakami-Murofushi, Synthesis of enantiomers 2-carboxy-cyclic phosphatic acid and effects of its chirality on biological functions, Biochem. Biophys. Acta 1811 (2011) 271–277.
[16] S. Yamamoto, K. Yamashina, K. Iwasa, M. Gotoh, S. Yagishita, K. Murayama, K. Murakami-Murofushi, K. Yoshikawa, Protective and therapeutic role of 2-carboxy-cyclic phosphatic acid in demyelinating disease, J. Neuroinflammation 14 (2017) 142.
[17] K. Hashimoto, M. Nakashima, A. Manato, M. Gotoh, H. Ikeshima-Kataoka, K. Murakami-Murofushi, Y. Miyamoto, 2-carboxy cyclic phosphatic acid suppresses inflammation via regulation of microglial activation in the sub-wounded mouse cerebral cortex, Sci. Rep. 8 (2018) 9715.
[18] M. Gotoh, A. Nagano, R. Tsukahara, H. Murofushi, K. Murakami-Murofushi, Cyclic phosphatic acid relieves osteoarthritis symptoms, Mol. Pain 10 (2014) 52.
[19] H. Yuuki, K. Kano, R. Koe, A. Inoue, J. Aski, LP3 locates LP6 signalling to non-contact sites in endothelial cells, J. Cell Sci. 128 (2015) 3871–3877.
[20] J.U. Johansson, S. Pradhan, L.A. Lokteva, N.S. Woodling, N. Ko, H.D. Brown, Q. Wang, C. Loh, E. Grkanaviciute, M. Buchwalter, A.B. Manning-Bog, K.I. Andreasson, Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia, J. Neurosci. 33 (2013) 16016–16032.
[21] E.H.C. Tang, P. Libby, P.M. Vanhoutte, A. Xu, Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases, J. Cardiovasc. Pharmacol. 59 (2012) 116–123.
[22] S. Palumbo, C.D. Toscano, L. Parente, R. Weigert, F. Bosetti, The cyclooxygenase-2 pathway via the PGEP2 EP2 receptor contributes to oligodendroyces apoptosis in cuprizone-induced demyelination, J. Neurochem. 121 (2012) 418–427.
[23] Y.S. Baek, S. Haas, H. Hackstein, G. Bein, M. Hernandez-Santana, H. Lehrach, S. Sauer, H. Seitz, Identification of novel transcriptional regulators involved in macrophage differentiation and activation in U937 cells, B.M.C. Immunology 10 (2009) 18.
[24] E. Stachowska, B. Dolegoswka, V. Dziedzioletko, M. Rybicka, M. Kaczmarczyk, J. Bober, M. Rac, M. Machalski, D. Chlebus, Prostaglandin E2 (PGE2) and thrombomodulin A2 (TXA2) synthesis is regulated by conjugated linoleic acids (CLA) in human macrophages, J. Physiol. Pharmacol. 60 (2009) 77–85.
[25] J.F. Figueiredo, R. Barhoumi, M. Raffaelli, S.D. Lawhon, B. Rousseau, R.C. Burghardt, R.M. Tsolis, A. J Bäumler, L.G. Adams, Salmonella enterica serovar Typhimurium-induced internalization and IL-8 expression in Hela cells does not have a direct relationship with intracellular Ca2+ levels, Microb. Infect. 11 (2009) 597–603.
[26] A. Grkovich, C.A. Johnson, M. Buczynski, E.A. Dennis, Lipopolysaccharide-in- duced Cyclooxygenase-2 expression in human U937 macrophages is phosphatic acid phosphohydrolase-1-dependent, J. Biol. Chem. 281 (2006) 52978–52987.
[27] J. Rupp, H. Kothe, A. Mueller, M. Maass, K. Dalho, Imbalanced secretion of IL-1b by differentiated THP-1 cells. (A) Effect of 2ccPA on PGE2 secretion in differentiated THP-1 treated with LPS. (**)p < 0.0001 vs. Vehicle. (B&)& C Differentiated THP-1 cells were incubated with LPS (1 μg/ml) in the presence of 2ccPA (10 μM) for 4 h. The cells were collected and the Ep2 (B) and Ep4 (C) mRNA expressions were analyzed by real-time PCR. (**p < 0.05; **p < 0.01 vs. Vehicle). (B&)& C Differentiated THP-1 cells were incubated with LPS (1 μg/ml) in the presence of 2ccPA (10 μM) for 4 h. The cells were collected and the Ep2 (B) and Ep4 (C) mRNA expressions were analyzed by real-time PCR. (**p < 0.05; **p < 0.01 vs. Vehicle).